PGNY Overview

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.

Wall Street analysts forecast PGNY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PGNY is29.75 USD with a low forecast of 26.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Progyny Inc revenue for the last quarter amounts to 318.40M USD, increased 6.69

Progyny Inc. EPS for the last quarter amounts to 0.14 USD, increased 27.27

Progyny Inc (PGNY) has 856 emplpoyees as of April 17 2026.

Today PGNY has the market capitalization of 1.40B USD.